

January 30, 2020 NIPRO CORPORATION

Announcement about Acquisition of Shares (Conversion into Subsidiary) of Medical Device Company in Bangladesh

Nipro Corporation ("Nipro") hereby announces that Nipro Asia Pte Ltd., its subsidiary for medical devices (main office: Singapore; President: Seigo Tsuchiya; hereinafter, "NIA"), has converted JMI Marketing Ltd., a medical device company in the People's Republic of Bangladesh (main office: Dhaka; Managing Director: Md. Abdur Razzaq; hereinafter, "JML") into a subsidiary by subscribing shares of JML allocated to a third party.

1. Reason for acquiring shares

News

Release

JML has secured a large market share in Bangladesh's rapidly growing economy for disposable medical devices including syringes, infusion sets, and IV catheters. For this reason, Nipro has concluded that further expansion of its share as well as its businesses can be expected in this market through capital participation.

2. How Nipro acquired shares

Nipro subscribed 2,179,333 shares that JML allocated to a third party, which resulted in holding 70% voting rights for JML. Nipro is scheduled to make JML a consolidated subsidiary.

Company name	JMI Marketing Ltd.	
Main office	Unique Heights, Level-11, 117, Kazi Nazrul Islam	
	Avenue, Ramna, Dhaka-1217, Bangladesh	
Representatives	Chairman: Jabed Iqbal Pathan	
	Managing Director: Md. Abdur Razzaq	
Capital	92,400,000 Bangladeshi taka (about 116,000,000 yen)	
Established	May 16, 2017	
Major shareholders and	Jabed Iqbal Pathan: 36.4%	
holding ratios	Md. Abdur Razzaq: 63.6%	
Main business	Sales of syringes, infusion sets, and other medical devices	

3. Overview of JMI Marketing Ltd.





Net sales	604,000,000 Bangladeshi taka (about 780,000,000 yen)
Number of employees	258 (as of the end of November 2018)

Number of shares acquired and status of shares held before/after the acquisition 4.

(1) Number of shares held before the acquisition:	0 shares
---	----------

(Percentage of voting rights held: 0.00%)

(2) Number of shares acquired: 2,179,333

(3) Number of shares held after the acquisition: 2,179,333

(Percentage of voting rights held: 70.00%)

Acquisition schedule 5.

(1)	Date of Nipro Board of Directors resolution:	August 27, 2019
(2)	Date of JML Board of Directors resolution:	November 3, 2019
(3)	Date of shares acquisition:	November 30, 2019

(3) Date of shares acquisition:

Business impact 6.

The impact of the acquisition on the consolidated financial results is expected to be small in this quarter.